Xtl Biopharmaceuticals (XTLB) Non Operating Investment Income (2009 - 2016)
Xtl Biopharmaceuticals (XTLB) posted quarterly Non Operating Investment Income of $84000.0 for Q2 2016, up 833.33% on a QoQ basis from $9000.0 in Q3 2009.
Xtl Biopharmaceuticals (XTLB) Non Operating Investment Income (2009 - 2016) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Non Operating Investment Income for 2 consecutive years, with $84000.0 the latest figure, recorded in Q2 2016.
- Quarterly Non Operating Investment Income changed N/A year-over-year to $84000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was -$7.1 million (changed N/A YoY) and the FY2025 annual result came in at $5000.0, down 97.01% from the prior year.
- Non Operating Investment Income rose to $84000.0 in Q2 2016 per XTLB's latest filing, from $9000.0 in the prior quarter.
- Over the last five years, Non Operating Investment Income for XTLB reached as high as $84000.0 in Q2 2016 and fell as low as $84000.0 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | - |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 84,000.00 |
| Jun 30, 2016 | 84,000.00 |
| Sep 30, 2009 | 9,000.00 |
| Sep 30, 2009 | 9,000.00 |
| Jun 30, 2009 | 1.21 Mn |
| Jun 30, 2009 | 1.21 Mn |